Table 2.
Reported cases of POTS related to vaccine COVID-19.
| Reference | Age/sex | Dose/timing | Medical history | Marker of autoimmunity |
|---|---|---|---|---|
| Reddy et al. (120) | 42/male | First/6 days | Hypothyroidism and B12 deficiency | Unknown |
| Hermel et al. (79) | 46/female | First/48 h | Allergic rhinitis and COVID-19 infection 2 months earlier | Unknown |
| Park et al. (121) | 40/male | First/7 days | Healthy | Negative |
| Sanada et al. (122) | 13/male | Second/1 day | Healthy | Negative |
| Maharaj et al. (123) | 15/male | Second/14 days | Healthy | Unknown |
| Rowe et al. (124) | 56/male | Second/5 days | Hypertension | + alpha-3 ganglionic acetylcholine receptor |
| Karimi Galougahi et al. (125) | 29/male | First/4 days | Healthy | ANA+ |
| Eldokla et al. (74) | 37/female | First/7 days | Seasonal allergy and depression | Negative |
| 21/female | First/12 days | Healthy | + ganglionic-acetylcholine receptor | |
| 46/female | First/14 days | Healthy | + Peroxidase antibody | |
| 19/female | Second/18 days | Healthy | ANA+, IL-10, factor necrosis tumor alpha | |
| 17/female | Second/21 days | Healthy | Elevated Il-2, Il-10, Il-13 |